Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Delayed Data from NSDQ)

$143.31 USD

143.31
479,138

-0.40 (-0.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $143.37 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for ALNY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 2,439 2,192 2,436 1,874 1,536
Receivables 328 238 199 602 43
Notes Receivable 0 0 0 0 0
Inventories 89 129 86 75 56
Other Current Assets 126 133 88 63 80
Total Current Assets 2,983 2,692 2,809 2,615 1,716
Net Property & Equipment 526 523 502 465 425
Investments & Advances 49 49 41 41 15
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 72 66 60 45 18
Total Assets 3,830 3,546 3,643 3,407 2,395
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 56 98 73 52 50
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 713 545 395 356 197
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 158 82 187 141 78
Total Current Liabilities 968 768 696 585 353
Mortgages 0 0 0 0 0
Deferred Taxes/Income 188 194 152 225 318
Convertible Debt 1,021 1,017 0 0 0
Long-Term Debt 0 0 676 191 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1,631 1,465 1,250 1,096 9
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 4,051 3,705 3,055 2,391 956
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 6,811 6,455 6,058 5,644 5,201
Retained Earnings -7,010 -6,569 -5,438 -4,585 -3,727
Other Equity -23 -45 -33 -44 -37
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -221 -158 588 1,016 1,439
Total Liabilities & Shareholder's Equity 3,830 3,546 3,643 3,407 2,395
Total Common Equity -221 -158 588 1,016 1,439
Shares Outstanding 125.40 123.00 119.60 116.10 111.40
Book Value Per Share -1.76 -1.29 4.92 8.75 12.91

Fiscal Year End for Alnylam Pharmaceuticals, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 2,439 2,406 2,058 2,071
Receivables NA 328 325 221 219
Notes Receivable NA 0 0 0 0
Inventories NA 89 96 100 132
Other Current Assets NA 126 158 145 119
Total Current Assets NA 2,983 2,985 2,524 2,541
Net Property & Equipment NA 526 526 527 523
Investments & Advances NA 49 49 49 49
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 72 75 93 63
Total Assets NA 3,830 3,839 3,402 3,392
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 56 74 60 62
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 713 713 599 509
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 158 121 88 60
Total Current Liabilities NA 968 950 789 673
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 188 196 194 191
Convertible Debt NA 1,021 1,020 1,019 1,018
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1,592 1,556 1,509
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 4,051 4,005 3,811 3,651
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 6,811 6,737 6,647 6,522
Retained Earnings NA -7,010 -6,872 -7,019 -6,743
Other Equity NA -23 -32 -37 -39
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA -221 -166 -408 -259
Total Liabilities & Shareholder's Equity NA 3,830 3,839 3,402 3,392
Total Common Equity 0 -221 -166 -408 -259
Shares Outstanding 125.90 125.40 125.40 125.00 124.50
Book Value Per Share 0.00 -1.76 -1.32 -3.27 -2.08